In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma
Authors:
- Robin G. RajanRRRobin G. Rajan
- Virneliz Fernandez-VegaVFVirneliz Fernandez-Vega
- Jantzen SperryJSJantzen Sperry
- Jonathan NakashimaJNJonathan Nakashima
- Long H. DoLDLong H. Do
- Warren AndrewsWAWarren Andrews
- Simina BocaSBSimina Boca
- Rezwanul IslamRIRezwanul Islam
- Sajeel A. ChowdharySCSajeel A. Chowdhary
- Jan SeldinJSJan Seldin
- Glauco R. SouzaGSGlauco R. Souza
- Louis ScampaviaLSLouis Scampavia
Open Access
Abstract
Background: Genomic profiling cannot solely predict the complexity of how tumor cells behave in their in vivo microenvironment and their susceptibility to therapies. The aim of the study was to establish a functional drug prediction model utilizing patient-derived GBM tumor samples for in vitro testing of drug efficacy followed by in vivo validation to overcome the disadvantages of a strict pharmacogenomics approach. Methods: High-throughput in vitro pharmacologic testing of patient-derived GBM tumors cultured as 3D organoids offered a cost-effective, clinically and phenotypically relevant model, inclusive of tumor plasticity and stroma. RNAseq analysis supplemented this 128-compound screening to predict more efficacious and patient-specific drug combinations with additional tumor stemness evaluated using flow cytometry. In vivo PDX mouse models rapidly validated (50 days) and determined mutational influence alongside of drug efficacy. We present a representative GBM case of three tumors resected at initial presentation, at first recurrence without any treatment, and at a second recurrence following radiation and chemotherapy, all from the same patient. Results: Molecular and in vitro screening helped identify effective drug targets against several pathways as well as synergistic drug combinations of cobimetinib and vemurafenib for this patient, supported in part by in vivo tumor growth assessment. Each tumor iteration showed significantly varying stemness and drug resistance. Conclusions: Our integrative model utilizing molecular, in vitro, and in vivo approaches provides direct evidence of a patient’s tumor response drifting with treatment and time, as demonstrated by dynamic changes in their tumor profile, which may affect how one would address that drift pharmacologically.Keywords
Funding Information
- Helene and Stephen Weicholz Foundation (R33CA206949)
- National Cancer Institute (R33CA206949)
This publication has 46 references indexed in Scilit:
- Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged SurvivalCell Stem Cell, 2014
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal CancerClinical Cancer Research, 2012
- The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and MenClinical Cancer Research, 2012
- Chemoresistance in gliomasMolecular and Cellular Biochemistry, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- Identification of human brain tumour initiating cellsNature, 2004
- Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human GlioblastomaCancer Research, 2004
- Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitroGlia, 2002
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999